AML

Dr Eytan M Stein breaks down how patients with MDS are risk-stratified, and how the clinical outcomes differ between risk groups.

In an interview with Targeted Oncology, Naval G. Daver, MD, discussed the approved and investigational CD47 monoclonal antibodies for patients with acute myeloid leukemia and myelodysplastic syndrome and where research is taking this space.

Naval G. Daver, MD, discusses the latest research on magrolimab, a CD47 monoclonal antibody, for patients with acute myeloid leukemia and myelodysplastic syndrome.

AUGMENT-101 demonstrates the potential of menin inhibitors for the treatment of patients with acute myeloid leukemia.

Results from the phase 3 AGILE study presented at SOHO 2022 show that ivosidenib plus azacitidine prolong event-free and overall survival with good responses vs placebo in patients with IDH1-mutated acute myeloid leukemia

Hetty Carraway, MD, describes how MDS differs from acute myeloid leukemia (AML), and the percentage of patients who progress to AML from MDS.

Eytan M. Stein, MD, provides an overview of myelodysplastic syndrome, including risk factors, symptoms, and diagnosis.

FLT3 tyrosine kinase inhibitor combination regimens may hold promise to not only improve outcomes for older individuals with FLT3-mutant but potentially for all patients , regardless of age or fitness.

Melhem Solh, MD, discusses his research on post-transplant outcomes of patients with TP53-mutant acute myeloid leukemia and myelodysplastic syndrome.

In an interview with Targeted Oncology, Eunice S. Wang, MD, discussed the growing use of menin inhibitors in acute myeloid leukemia, and clinical trial research further supporting the treatment strategy.

The FDA has cleared TakeAim Leukemia study to continue enrolling emavusertib with or without azacytidine and venetoclax in patients with acute myeloid leukemia or myelodysplastic syndrome.

Due to suspected cases of fatal differentiation syndrome in a clinical trial, the FDA has placed a full clinical hold on the study of FHD-286 in acute myeloid leukemia and myelodysplastic syndrome.

A phase 1b/2 clinical trial aims to evaluate the safety of lanraplenib plus gilteritinib in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia.

According to results from the QuANTUM-First, quizartinib significantly improved overall survival vs standard of care in patients with newly diagnosed FLT3 ITD–positive acute myeloid leukemia.

Siddhartha Mukherjee, MD, discusses potential means of targeting chimeric antigen receptor T-cell therapy for patients with acute myeloid leukemia.

Marcin Kortylewski, PhD, discusses what research he believes is next to come in the acute myeloid leukemia space.

In a phase 1 clinical trial, treatment with GFH009 showed early signal s of efficacy in patients with advanced relapsed or refractory lymphoma and acute myeloid leukemia.

Gilteritinib monotherapy reacts favorably and led to higher rates of composite complete remissions in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia who received prior midostaurin or sorafenib.

According to , results from a phase 1 study support that on-target magrolimab-mediated anemia is manageable in patients with high-risk myelodysplastic syndrome and acute myeloid leukemia.

BTX-1188 could prevent systemic inflammatory dose-limiting toxicities that are usually attributed to pure GSPT1 degradation due to its immunomodulatory properties from the IKZF1/3 degradation.

Phase 3 AGILE results show that ivosidenib plus azacitidine has clinical activity in IDH1-mutant acute myeloid leukemia.

The FDA has granted approval for ivosidenib tablets as treatment for patients with previously untreated IDH1-mutated acute myeloid leukemia.

Melhem Solh, MD, discussed how the post transplantation outcomes for patients with MDS and AML with the TP53 gene mutation have changed to what it is today.

A partial clinical hold has been placed by the FDA on a phase 1 trial examining the use of FHD-286 as treatment for patients with relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome.

In an interview with Targeted Oncology™, Siddhartha Mukherjee, MD, examined the current treatment landscape for acute myeloid leukemia and therapies on the horizon.